the invention relates to a method of treatment of the subject is affected with multiple sclerosis or showing a clinically isolated syndrome, involving the introduction of actor \u0444\u0430\u043c\u043f\u0440\u0438\u0434\u0438\u043d\u0430 as additional therapy or in combination with \u043b\u0430\u043a\u0432\u0438\u043d\u0438\u043c\u043e\u0434\u043e\u043c.the invention also relates to the packaging of these funds, including \u043b\u0430\u043a\u0432\u0438\u043d\u0438\u043c\u043e\u0434 and \u0444\u0430\u043c\u043f\u0440\u0438\u0434\u0438\u043d, for the treatment of the subject is affected with multiple sclerosis or dr. \u0435\u043c\u043e\u043d\u0441\u0442\u0440\u0438\u0440\u0443\u044e\u0449\u0435\u0433\u043e clinically isolated syndrome.further, the invention relates to \u0444\u0430\u043c\u043f\u0440\u0438\u0434\u0438\u043d\u0443 for use as a supplementary therapy or in combination with \u043b\u0430\u043a\u0432\u0438\u043d\u0438\u043c\u043e\u0434\u043e\u043c in treatment of the subject, the affected race permanent showing a clinically isolated syndrome or multiple sclerosis.further, the invention relates to pharmaceutical compositions comprising \u043b\u0430\u043a\u0432\u0438\u043d\u0438\u043c\u043e\u0434 and \u0444\u0430\u043c\u043f\u0440\u0438\u0434\u0438\u043d, for use in the treatment of the subject is affected with sclerosis om or showing a clinically isolated syndrome.in addition, the invention relates to the use of \u043b\u0430\u043a\u0432\u0438\u043d\u0438\u043c\u043e\u0434\u0430 and \u0444\u0430\u043c\u043f\u0440\u0438\u0434\u0438\u043d\u0430 gain combination for the treatment of the subject is affected with multiple sclerosis or \u0434\u0435\u043c\u043e\u043d\u0441 \u0442\u0440\u0438\u0440\u0443\u044e\u0449\u0435\u0433\u043e clinically isolated syndrome.Изобретение относится к способу лечения субъекта, пораженного рассеянным склерозом или демонстрирующего клинически изолированный синдром, включающему введение субъекту фампридина в виде дополнительной терапии и
